Renalytix Plc (LON:RENX – Get Free Report) rose 22.4% during mid-day trading on Tuesday . The stock traded as high as GBX 2.50 and last traded at GBX 2.33. Approximately 3,694,300 shares changed hands during mid-day trading, an increase of 342% from the average session volume of 835,273 shares. The stock had previously closed at GBX 1.90.
Renalytix Price Performance
The stock has a market capitalization of £9.83 million, a P/E ratio of -0.56 and a beta of 1.81. The business’s 50 day simple moving average is GBX 1.82 and its two-hundred day simple moving average is GBX 3.43. The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
